Humanized anti-IL-18 antibodies
The present invention discloses humanized anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.
1. A pharmaceutical composition comprising a pharmaceutical carrier and a humanized anti-interleukin-18 antibody; said humanized anti-interleukin-18 antibody comprising:
a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 19, and SEQ ID NO: 23; and
a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 15 and SEQ ID NO: 31.
2. The pharmaceutical composition of claim 1 , wherein said humanized anti-interleukin-18 antibody comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 11 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 15, or a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 11 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 31.
3. The pharmaceutical composition of claim 1 , wherein said humanized anti-interleukin-18 antibody comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 19 and a light chain comprising the amino acid sequence shown in SEQ ID NO:15, or a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 19 and a light chain comprising the amino acid sequence shown in SEQ ID NO: 31.
4. A pharmaceutical composition comprising a pharmaceutical carrier and a humanized anti-interleukin-18 antibody; said humanized anti-interleukin-18 antibody comprising a heavy chain comprising the amino acid sequence shown in SEQ ID NO:23 and a light chain comprising the amino acid sequence shown in SEQ ID NO:15, or a heavy chain comprising the amino acid sequence shown in SEQ ID NO:23 and a light chain comprising the amino acid sequence shown in SEQ ID NO:31.
5. A pharmaceutical composition comprising a pharmaceutical carrier and a humanized anti-interleukin-18 antibody; said humanized anti-interleukin-18 antibody comprising a heavy chain comprising the amino acid sequence shown in SEQ ID NO:11 and a light chain comprising the amino acid sequence shown in SEQ ID NO:15.
6. A pharmaceutical composition comprising a pharmaceutical carrier and a humanized anti-interleukin-18 antibody; said humanized anti-interleukin-18 antibody comprising a heavy chain comprising an amino acid sequence selected from the group consisting of: the amino acid sequence shown in SEQ ID NO:11, the amino acid sequence shown in SEQ ID NO:19, and the amino acid sequence shown in SEQ ID NO:23.
7. A pharmaceutical composition comprising a pharmaceutical carrier and a humanized anti-interleukin-18 antibody; said humanized anti-interleukin-18 antibody comprising a light chain comprising an amino acid sequence selected from the group consisting of: the amino acid sequence shown in SEQ ID NO:15 and the amino acid sequence shown in SEQ ID NO:31.